drug
Novel Therapeutic
Preclinicalupdated 6mo agoby Rosalind Franklin University of Medicine and Science
Preclinicalcommunity read0 votes
🐶 often sniffed alongside
top 1all catalysts(0)
nothing on the calendar yet
News(10)
- China has a clear shot to 2030 goals, though economic, cultural barriers remainTo grow into a biopharma juggernaut, China aims to become the leading source of innovative medicines on the global markets—a goal that experts say the country is on track to hit.biospace · 8d ago
- BioArctic left out in the cold as Novartis walks away from $800M neuro collabJust 14 months after Novartis signed an $800 million biobucks neuroscience partnership with BioArctic, the Swiss pharma has walked away from the deal.fiercebiotech · 16d ago
- UniQure snags May Day decision date for Huntington’s gene therapy after arduous yearAfter a year of controversial regulatory reversals, the FDA has accepted uniQure’s application for ifezuntirgene inilparvovec for priority review, with a May 1 action date. If approved, the therapy…biospace · 16d ago
- Why investors are taking another look at kidney diseaseIn this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene ther…biospace · 27d ago
- Syndax ends fibrosis program for Niktimvo after mid-stage disappointmentSyndax Pharmaceuticals will no longer test Niktimvo for idiopathic pulmonary fibrosis, but the company’s work to expand the drug’s label in chronic graft-versus-host disease, for which it was appro…biospace · 1mo ago
- CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drugAustralia’s CSL is paying $355 million upfront for the rights to Alentis Therapeutics’ phase 2-stage fibrosis drug.fiercebiotech · 1mo ago
- BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readoutBioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.fiercebiotech · 2mo ago
- Epigenetic editing shows promise against chronic hep B infectionsA new method of CRISPR-based gene editing shows promise in curtailing chronic hepatitis B infections. Its twist is to silence disease-causing genes without altering the underlying DNA. Tune Therape…endpoints · 5mo ago
- Dr Garzotto on Aglatimagene Besadenovec Plus Valacyclovir and EBRT in Localized Prostate CancerMark Garzotto, MD, discusses efficacy data with aglatimagene besadenovec plus valacyclovir and EBRT in localized prostate cancer.onclive · 6mo ago
- Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical PracticeSanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.onclive · 6mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that